Literature DB >> 35373288

Are TEMs Canceled? Questioning the Functional Relevance of Tie2-Expressing Macrophages.

Yuqing Zhang1,2, Rolf A Brekken1,2,3.   

Abstract

Inflammatory cells are a vital component of the tumor stroma and, of these, tumor-associated macrophages (TAM) are the major cell type. TAMs are recruited early in tumorigenesis and generally promote metastasis, stimulate tumor angiogenesis, and drive immunosuppression. TAMs have been shown to express the endothelial cell markers that enable chemotaxis and proangiogenic capacity. In this issue of Cancer Research, Jakab and colleagues challenge the functional significance of Tie2-expressing monocytes/macrophages (TEM) in the context of tumor growth and progression. By employing myeloid-specific deletion of the angiopoietin receptor Tie2 and comprehensive analysis of myeloid cell single-cell RNA sequencing datasets, they provide compelling data that Tie2-positive macrophages do not contribute to tumor angiogenesis or relapse after chemotherapy, two major biologic processes previously attributed to tumor-associated TEMs. The study highlights that the concept of macrophage-expressed Tie2 as a therapeutic target or prognostic indicator needs reconsideration. See related article by Jakab et al., p. 1353. ©2022 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35373288      PMCID: PMC9145315          DOI: 10.1158/0008-5472.CAN-22-0330

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   13.312


  10 in total

1.  Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells.

Authors:  Naoki Horikawa; Kaoru Abiko; Noriomi Matsumura; Junzo Hamanishi; Tsukasa Baba; Ken Yamaguchi; Yumiko Yoshioka; Masafumi Koshiyama; Ikuo Konishi
Journal:  Clin Cancer Res       Date:  2016-07-11       Impact factor: 12.531

2.  The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors.

Authors:  Allison S Harney; George S Karagiannis; Jeanine Pignatelli; Bryan D Smith; Ece Kadioglu; Scott C Wise; Molly M Hood; Michael D Kaufman; Cynthia B Leary; Wei-Ping Lu; Gada Al-Ani; Xiaoming Chen; David Entenberg; Maja H Oktay; Yarong Wang; Lawrence Chun; Michele De Palma; Joan G Jones; Daniel L Flynn; John S Condeelis
Journal:  Mol Cancer Ther       Date:  2017-08-24       Impact factor: 6.261

3.  Tie2 Receptor in Tumor-Infiltrating Macrophages Is Dispensable for Tumor Angiogenesis and Tumor Relapse after Chemotherapy.

Authors:  Moritz Jakab; Till Rostalski; Ki Hong Lee; Carolin Mogler; Hellmut G Augustin
Journal:  Cancer Res       Date:  2022-04-01       Impact factor: 13.312

4.  Tie2 Expression on Macrophages Is Required for Blood Vessel Reconstruction and Tumor Relapse after Chemotherapy.

Authors:  Lin Chen; Jie Li; Fei Wang; Chengliang Dai; Fan Wu; Xiaoman Liu; Taotao Li; Rainer Glauben; Yi Zhang; Guangjun Nie; Yulong He; Zhihai Qin
Journal:  Cancer Res       Date:  2016-10-10       Impact factor: 12.701

5.  Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells.

Authors:  D I Gabrilovich; H L Chen; K R Girgis; H T Cunningham; G M Meny; S Nadaf; D Kavanaugh; D P Carbone
Journal:  Nat Med       Date:  1996-10       Impact factor: 53.440

6.  Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors.

Authors:  Michele De Palma; Mary Anna Venneri; Rossella Galli; Lucia Sergi Sergi; Letterio S Politi; Maurilio Sampaolesi; Luigi Naldini
Journal:  Cancer Cell       Date:  2005-09       Impact factor: 31.743

7.  VEGFR2 activity on myeloid cells mediates immune suppression in the tumor microenvironment.

Authors:  Yuqing Zhang; Huocong Huang; Morgan Coleman; Arturas Ziemys; Purva Gopal; Syed M Kazmi; Rolf A Brekken
Journal:  JCI Insight       Date:  2021-12-08

8.  Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells.

Authors:  Michele De Palma; Mary Anna Venneri; Cristina Roca; Luigi Naldini
Journal:  Nat Med       Date:  2003-05-12       Impact factor: 53.440

9.  The miR-126-VEGFR2 axis controls the innate response to pathogen-associated nucleic acids.

Authors:  Judith Agudo; Albert Ruzo; Navpreet Tung; Hélène Salmon; Marylène Leboeuf; Daigo Hashimoto; Christian Becker; Lee-Ann Garrett-Sinha; Alessia Baccarini; Miriam Merad; Brian D Brown
Journal:  Nat Immunol       Date:  2013-11-24       Impact factor: 25.606

10.  Real-Time Imaging Reveals Local, Transient Vascular Permeability, and Tumor Cell Intravasation Stimulated by TIE2hi Macrophage-Derived VEGFA.

Authors:  Allison S Harney; Esther N Arwert; David Entenberg; Yarong Wang; Peng Guo; Bin-Zhi Qian; Maja H Oktay; Jeffrey W Pollard; Joan G Jones; John S Condeelis
Journal:  Cancer Discov       Date:  2015-08-12       Impact factor: 39.397

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.